Composition: Linagliptin + Metformin HCl; (2.5mg+500mg), (2.5mg + 850mg) & (2.5mg + 1000mg) Tablet.

Indication: Linagliptin and Metformin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Linagliptin and Metformin is appropriate.

Dosage & Administration: Adult: In patients currently not treated with Metformin, the initiate dose is one tablet twice daily. Or, as directed by the registered physician.

Side effects: The most common side effects are nasopharyngitis and diarrhoea. Other side effects are urticaria, angioedema, or bronchial hyperreactivity, cough, decreased appetite, nausea, vomiting, pruritus, pancreatitis and myalgia.

Contraindications: It is contraindicated in patients with known hypersensitivity to any other components of this drug. This medicine is also contraindicated for following patients: Renal impairment, acute or chronic metabolic acidosis including diabetic ketoacidosis.

Precautions: This medicine is not recommended in hepatic impairment or hypoxic states. When used with a sulfonylurea, a lower dose of the sulfonylurea may be required to reduce the risk of hypoglycemia.

Use in Pregnancy and Lactation: Pregnancy category B. There are no adequate and well controlled studies in pregnant woman. This tablets should be used during pregnancy only if clearly needed. Caution should be exercised

## Linarol-M

## Tablet

when this tablet is administered to a nursing woman.

Drug-interactions: Metformin: Concomimitent administration of cationic drugs are digoxin, ranitidine, triamterene, vancomycin etc. may reduce metformin elimination. Linagliptin: The efficacy of this tablet may be reduced when administered in combination with rifampin.

## Packing:

**Linarol-M 500**: 1 x 14's tablets in blister pack.

**Linarol-M 850**: 1 x 14's tablets in blister

**Linarol-M 1000** : 1 x 14's tablets in blister pack.